National Research Center for Translational Medicine · Shanghai—National Key Scientific Infrastructure for Translational Medicine by unknown
SCIENCE CHINA 
Life Sciences 
© The Author(s) 2016. This article is published with open access at link.springer.com life.scichina.com   link.springer.com 
                  
*Corresponding author (email: sjchen@stn.sh.cn) 
SPECIAL TOPIC: Translational medicine in China II October 2016  Vol.59  No.10: 1051–1054 
• NEWS AND VIEWS • doi: 10.1007/s11427-016-5099-1 
National Research Center for Translational Medicine· Shanghai—— 
National Key Scientific Infrastructure for Translational Medicine 
Chao-Jun Wen & Sai-Juan Chen* 
Collaborative Innovation Center of Systems Biomedicine, National Research Center for Translational Medicine· Shanghai; State Key 
Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University 
School of Medicine, Shanghai, 200025, China 
 
Citation:  Wen, C.J., and Chen, S.J. (2016). National Research Center for Translational Medicine· Shanghai—National Key Scientific Infrastructure for 




In July 2013, the National Development and Reform Com-
mission formally approved the “National Research Center 
for Translational Medicine· Shanghai” (hereinafter “the 
Center”), a piece of the national key scientific infrastruc-
ture. As a national-level institution, the Center will be 
co-administered by the Ministry of Education and the 
Shanghai Municipal Government. While affiliated with 
Shanghai Jiao Tong University (SJTU), the Center will also 
integrate the biomedical forces of universities and scientific 
institutions in Shanghai, including Fudan University, Tongji 
University, Shanghai Institutes for Biological Sciences, and 
the Chinese Academy of Sciences. It will also closely col-
laborate with industries, with a goal of developing into a 
multidisciplinary, open and internationally influential base 
for translational medical research. This key scientific infra-
structure will also be supported in terms of running costs 
and research personnel by the Collaborative Innovation 
Center for Systems Biomedicine of the Ministry of Educa-
tion, which is being established. Professor Sai-Juan Chen, a 
member of the Chinese Academy of Engineering, has been 
appointed as Director of the Center. 
BACKGROUND 
With the rapid development of the social economy and the 
emergence of new challenges to health including environ-
mental deterioration, aging and change of lifestyles, China 
is facing challenges in a complex disease spectrum charac-
teristic of both developing and developed countries. While 
communicable diseases remain a heavy burden, chronic 
non-communicable diseases, such as cancer, cardiovascular 
and cerebrovascular diseases and diabetes, have already 
become the leading causes of morbidity and mortality. 
Meanwhile, the healthcare system of the world’s most pop-
ulated country is under the dual pressure of limited medical 
resources and constantly increasing needs for medical ser-
vices. The quality of medical services must be improved 
while expenses be controlled. Furthermore, as in many 
countries, there are disjunctions between basic sciences and 
drug research and development, and between clinical trials 
and public health. To this end, the development of transla-
tional medicine represents both a necessity and an oppor-
tunity for China. 
The concept of translational research was pioneered by 
National Institutes of Health of US. It usually refers to ef-
forts directed toward converting basic biomedical research 
discoveries into effective new therapies and bringing clini-
cal observations back to the laboratory. In view of China’s 
national conditions, we have a unique understanding of 
translational research, which, in our view has a wider con-
notation than “from bench to bedside”. While clinical ap-
plication is stressed to benefit patients, preventive medicine 
to benefit the general population should also be emphasized. 
Medical research should extend from bench to public and 
community, look for effective measures for disease preven-
tion and control through epidemiologic studies for commu-
nity intervention, and provide evidence for public health 
policy-making.  
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SJTU and Rui-Jin Hospital are the two major supporting 
institutions of the Center. Both have sound foundations for 
translational research. SJTU is one of the top universities in 
the country. In July 2005, SJTU and Shanghai Second 
Medical University merged to form the new SJTU, jointly 
supported by the Shanghai Municipal Government and the 
Ministry of Education. The merge has promoted the interac-
tions of engineering, science and medicine, laying a solid 
foundation for translational research. Rui-Jin Hospital, 
where the clinical research building of the Center will be 
located, is a renowned general hospital with the rank of 
“Grade 3, Class A” (the highest level in China). In the past 
60 years, SJTU School of Medicine and Rui-Jin Hospital 
have made major contributions to the medical sciences in 
China and the world, including the successful treatment of 
patients with extensive burns led by Dr. Ji-Xiang Shi in the 
1950s and the first successful case of limb re-implantation 
in the world by Dr. Zhong-Wei Chen in the 1960s. In recent 
years, the novel and curative synergistic targeting therapy of 
acute promyelocytic leukemia, pioneered by the research 
team led by Prof. Zhen-Yi Wang, Prof. Zhu Chen and Prof. 
Sai-Juan Chen at Shanghai Institute of Hematology of 
Rui-Jin Hospital, has been widely recognized as a paradigm 
for translational research in the world. Rui-Jin Hospital has 
also made important achievements in the studies of meta-
bolic, cardiovascular and cerebrovascular diseases. 
Bio-banks of samples from 450,000 cases of metabolic dis-
eases and essential hypertension special phenotypic study 
cohorts have been set up.  
RESEARCH ORIENTATIONS 
The Center has adopted a “systematic three by three” re-
search scheme (Figure 1). Guided by the National Innova-
tion Strategies and National Mid- and Long-Term Guide-
lines for Scientific Development, and based on the ad-
vantages of SJTU and Rui-Jin Hospital, the research of the 
Center will be focused on three major types of 
life-threatening diseases: cancer, cardiovascular and cere-
brovascular diseases, and metabolic diseases. To carry out 
the research, the Center will prioritize building three main 
platforms: translational research core facilities, a resource 
sharing system, and a key technical supporting system. The 
priorities of the translational research core facilities will be 
given to research wards and a pathological study platform, 
which are crucial for the development of 4P (predictive, 
preventive, personalized and participatory) medicine. This 
will aim to improve clinical studies in China and develop 
standardized diagnosis and treatment protocols that keep to 
the norms of good clinical practice. The resource-sharing 
system includes standardized bio-banks (clinical cases and 
cohort studies), platforms for in-depth development and 
utilization of clinical resources, and comprehensive 
bio-information systems, providing and sharing valuable 
clinical (cohort) samples and relevant information for re-
searchers. Modern bioinformatics and biological statistics 
will be used to analyze data from clinical and basic re-
search, explore and discover the hidden biomedical rules, 
and provide one-stop information resource-sharing and 
analysis for clinical and basic researchers. The key technical 
supporting system includes a discovery and validation plat-
form for biological markers and drug targets, a “pre-trial” 
platform for new drugs and diagnostic reagents, an exploita-
tion platform for combined targeting therapeutics, and a 
development platform of new medical instruments, joint 
research laboratories and collaborative innovation laborato-
ries. After discovery, validation and pre-trial through the 
above platforms, the novel biomarkers, drug targets, the 
innovative technologies and products will be applied back 
to the research wards. The Center aims to develop a set of 
intelligent portable diagnostic equipment, and achieve 
breakthroughs in 1–2 technologically sophisticated medical 
equipment. Through the above research scheme, a great 
number of novel methods, drugs, reagents, instruments and 
technologies important to the early diagnosis, treatment and 
prevention of the three types of diseases will be developed. 
PILOT MANAGING SYSTEMS 
As the first national center on translational medicine, the  
 
 
Figure 1  (Color online) Systematic three by three research scheme of the Center. 
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Center aims at not only taking the lead in research but also 
serving as a model in exploring innovative management 
systems to promote the development of translational re-
search in China. 
ORGANIZATION STRUCTURE 
The Center, as a part of the national key scientific infra-
structure, is autonomous in its management. In the mean-
time, it is established as a new research institute of SJTU. 
The Director supervises the general administration of the 
Center under the leadership of the Board of Directors. For 
research, an accountability system of chief scientists has 
been established. A series of specialized committees has 
been set up, including a Scientific Advisory Board, Interna-
tional Consulting Committee and Ethics Committee   
(Figure 2). Funds for regular running of the Center will be 
provided through national, municipal and university chan-
nels. 
RUNNING SYSTEMS OF RESEARCH WARDS 
The Center plans to develop 300 research wards meeting 
international standards. This is the first attempt in China. 
With the rich clinical resources of Rui-Jin Hospital, the de-
velopment of such a large scale research wards will un-
doubtedly enhance the core competitiveness of the Center 
and endows the Center with much appeal for the researchers.  
Clinical trials must be approved by the Ethics Committee 
of the Center. A research team of qualified doctors and 
nurses will be formed to carry out clinical trials with quality 
and efficiency. All participants in the clinical trials will be 
free of charge in principle. The costs will be mainly covered 
by medical insurances, and in the meantime will be partially 
supported by the Shanghai Guangci Translational Medical 
Research Development Foundation which was established 
in 2014 with a specific mission to support the translational 
research in China. 
TALENT RECRUITMENT AND ASSESSMENT 
SYSTEMS 
Positions of chief scientists at the Center are open to high- 
caliber researchers from China and abroad. Preference will 
be given to those with a strong background and successful 
experiences in both clinical and basic studies or those hav-
ing expertise in multidisciplinary research. A search com-
mittee composed in part of the Scientific Advisory Board 
and International Consulting Committee members has been 
formed. Appropriate criteria will be adopted for the evalua-
tion of different types of researchers. In addition to the tra-
ditional publication-based criteria, importance will be at-
tached to the transfer and application of the laboratory dis-
coveries. 
Following the talent-oriented concept, the Center will 
strive to create appealing conditions for the talents. Com-
petitive salary and benefits depending on candidate's quali-
fications will be provided, with the support from national, 
municipal and university channels. 
FIVE-YEAR GOALS 
The Center aims to discover and validate series of molecu-
lar biomarkers and drug targets in the three major disease 
areas, acquire numerous domestic and international patents 
and new drug certificates, publish several papers in top in-
ternational journals, develop two or three new drugs or new 
treatment protocols and launch clinical trials, strive for new 
breakthroughs in synergistic targeted therapies for hemato- 
logical malignancies beyond acute promyelocytic leukemia,  
 
 
Figure 2  Organization structure of the Center. 
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and develop a series of cutting-edge diagnostic and treat-
ment instruments with intellectual property rights. In addi- 
tion, the Center will endeavor to build a world-class re- 
search team composed of 10–12 chief scientists and 50 
principal investigators. 
PERSPECTIVES 
Significantly, the Center will promote the organic integra-
tion of advantageous scientific resources in Shanghai and 
exert a profound influence in the whole country. It will ac-
celerate the development of innovative medical systems and 
boost the pharmaceutical industry in China. It will also 
promote industry-university-institution cooperation and thus 
contribute to the transformation of development models of 
the pharmaceutical industry in China. Additionally, it will 
help to reinforce the interactions of different disciplines. 
Meanwhile, the Center will serve as an incubator for cul-
turing world-class talent in the field of translational medi-
cine. 
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